Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (130)

Apr 20, 2043method-of-use (U-3778)US 11844797
Mar 2, 2043method-of-use (U-3419)US 11839612
Feb 23, 2043method-of-use (U-3419)US 11752144
Feb 23, 2043method-of-use (U-3419)US 12042473
Feb 23, 2043method-of-use (U-3419)US 12146889
Feb 15, 2043method-of-use (U-3419)US 11986444
Feb 15, 2043method-of-use (U-3419)US 12036191
Jan 23, 2043method-of-use (U-3419)US 11730706
Jan 23, 2043method-of-use (U-3419)US 11883373
Jan 20, 2043method-of-use (U-3419)US 11717518
Jan 20, 2043method-of-use (U-3419)US 11925636
Jan 20, 2043formulationUS 12156914
Jan 20, 2043method-of-use (U-3419)US 12310961
Jan 20, 2043method-of-use (U-3419)US 12357697
Dec 1, 2041method-of-use (U-3419)US 11896563
Dec 1, 2041method-of-use (U-3419)US 12390428
Jan 7, 2040method-of-use (U-3419)US 10780064
Jan 7, 2040method-of-use (U-3419)US 10925842
Jan 7, 2040method-of-use (U-3419)US 10940124
Jan 7, 2040method-of-use (U-3419)US 10966942
Nov 9, 2034method-of-use (U-3419)US 10780066
Nov 5, 2034method-of-use (U-3419)US 10058518
Nov 5, 2034method-of-use (U-3419)US 10064857
Nov 5, 2034method-of-use (U-3419)US 10080727
Nov 5, 2034method-of-use (U-3419)US 10092560
Nov 5, 2034method-of-use (U-3419)US 10092561
Nov 5, 2034method-of-use (U-3419)US 10105327
Nov 5, 2034method-of-use (U-3419)US 10105361
Nov 5, 2034method-of-use (U-3419)US 10251879
Nov 5, 2034method-of-use (U-3419)US 10463634
Nov 5, 2034method-of-use (U-3419)US 10512643
Nov 5, 2034method-of-use (U-3419)US 10548857
Nov 5, 2034method-of-use (U-3419)US 10596167
Nov 5, 2034method-of-use (U-3419)US 10772850
Nov 5, 2034method-of-use (U-3419)US 10786469
Nov 5, 2034method-of-use (U-3419)US 10786496
Nov 5, 2034method-of-use (U-3419)US 10799497
Nov 5, 2034method-of-use (U-3419)US 10806710
Nov 5, 2034method-of-use (U-3419)US 10864209
Nov 5, 2034method-of-use (U-3419)US 10874663
Nov 5, 2034method-of-use (U-3419)US 10874664
Nov 5, 2034method-of-use (U-3419)US 10874665
Nov 5, 2034method-of-use (U-3419)US 10881624
Nov 5, 2034method-of-use (U-3419)US 10881657
Nov 5, 2034method-of-use (U-3419)US 10894046
Nov 5, 2034method-of-use (U-3419)US 10894047
Nov 5, 2034method-of-use (U-3419)US 10898453
Nov 5, 2034method-of-use (U-3419)US 10933034
Nov 5, 2034method-of-use (U-3419)US 10945973
Nov 5, 2034method-of-use (U-3419)US 10966941
Nov 5, 2034method-of-use (U-3419)US 10966974
Nov 5, 2034method-of-use (U-3419)US 11020389
Nov 5, 2034method-of-use (U-3419)US 11058648
Nov 5, 2034method-of-use (U-3419)US 11065248
Nov 5, 2034method-of-use (U-3419)US 11090300
Nov 5, 2034method-of-use (U-3419)US 11096937
Nov 5, 2034method-of-use (U-3419)US 11123343
Nov 5, 2034method-of-use (U-3419)US 11123344
Nov 5, 2034method-of-use (U-3419)US 11129826
Nov 5, 2034method-of-use (U-3419)US 11141388
Nov 5, 2034method-of-use (U-3419)US 11141416
Nov 5, 2034method-of-use (U-3419)US 11147808
Nov 5, 2034method-of-use (U-3419)US 11185515
Nov 5, 2034formulationUS 11191739
Nov 5, 2034formulationUS 11197839
Nov 5, 2034method-of-use (U-3419)US 11207281
Nov 5, 2034method-of-use (U-3419)US 11213521
Nov 5, 2034method-of-use (U-3419)US 11229640
Nov 5, 2034method-of-use (U-3419)US 11234946
Nov 5, 2034method-of-use (U-3419)US 11253491
Nov 5, 2034method-of-use (U-3419)US 11253492
Nov 5, 2034method-of-use (U-3419)US 11273133
Nov 5, 2034method-of-use (U-3419)US 11273134
Nov 5, 2034method-of-use (U-3419)US 11285118
Nov 5, 2034method-of-use (U-3419)US 11285146
Nov 5, 2034method-of-use (U-3419)US 11291638
Nov 5, 2034method-of-use (U-3419)US 11291665
Nov 5, 2034method-of-use (U-3419)US 11298351
Nov 5, 2034method-of-use (U-3419)US 11298352
Nov 5, 2034method-of-use (U-3419)US 11311534
Nov 5, 2034method-of-use (U-3419)US 11344544
Nov 5, 2034method-of-use (U-3419)US 11357744
Nov 5, 2034method-of-use (U-3419)US 11364233
Nov 5, 2034method-of-use (U-3419)US 11382874
Nov 5, 2034method-of-use (U-3419)US 11419867
Nov 5, 2034method-of-use (U-3419)US 11426370
Nov 5, 2034method-of-use (U-3419)US 11426401
Nov 5, 2034formulationUS 11433067
Nov 5, 2034method-of-use (U-3419)US 11439636
Nov 5, 2034method-of-use (U-3419)US 11478468
Nov 5, 2034method-of-use (U-3419)US 11497721
Nov 5, 2034method-of-use (U-3419)US 11510918
Nov 5, 2034method-of-use (U-3419)US 11517542
Nov 5, 2034method-of-use (U-3419)US 11517543
Nov 5, 2034method-of-use (U-3419)US 11524007
Nov 5, 2034method-of-use (U-3419)US 11524008
Nov 5, 2034formulationUS 11534414
Nov 5, 2034method-of-use (U-3419)US 11541021
Nov 5, 2034method-of-use (U-3419)US 11541048
Nov 5, 2034method-of-use (U-3419)US 11571417
Nov 5, 2034method-of-use (U-3419)US 11576909
Nov 5, 2034method-of-use (U-3419)US 11590124
Nov 5, 2034method-of-use (U-3419)US 11596627
Nov 5, 2034method-of-use (U-3419)US 11617728
Nov 5, 2034method-of-use (U-3563)US 11617747
Nov 5, 2034method-of-use (U-3419)US 11779579
Nov 5, 2034method-of-use (U-3419)US 11969421
Nov 5, 2034method-of-use (U-3419)US 12109178
Nov 5, 2034method-of-use (U-3419)US 9168234
Nov 5, 2034method-of-use (U-3419)US 9198905
Nov 5, 2034method-of-use (U-3419)US 9205083
Nov 5, 2034method-of-use (U-3419)US 9238032
Nov 5, 2034method-of-use (U-3419)US 9278095
Nov 5, 2034method-of-use (U-3419)US 9314462
Nov 5, 2034method-of-use (U-3419)US 9370513
Nov 5, 2034method-of-use (U-3419)US 9375429
Nov 5, 2034method-of-use (U-3419)US 9408815
Nov 5, 2034method-of-use (U-3419)US 9421176
Nov 5, 2034method-of-use (U-3419)US 9457023
Nov 5, 2034method-of-use (U-3419)US 9457025
Nov 5, 2034method-of-use (U-3419)US 9474731
Nov 5, 2034method-of-use (U-3419)US 9486450
Nov 5, 2034method-of-use (U-3419)US 9700528
Nov 5, 2034method-of-use (U-3419)US 9700553
Nov 5, 2034method-of-use (U-3419)US 9707191
Nov 5, 2034method-of-use (U-3419)US 9763932
Nov 5, 2034method-of-use (U-3419)US 9861595
Nov 5, 2034method-of-use (U-3419)US 9867819
Nov 5, 2034method-of-use (U-3419)US 9968568
Oct 29, 2033formulationUS 8569328

News(3)

The FDA’s 505(b)(2) pathway is an underestimated engine of value creation
The biopharma industry would do well to re-embrace the 505(b)(2) path, which allows sponsors to draw on previous findings around an existing drug even as they propose modifications to it.
biospace · 25d ago
Summit’s ‘self-inflicted’ stumble; Esperion’s take-private deal
Summit’s decision to conduct an interim analysis of a closely watched trial backfired. Elsewhere, Axsome got a much-needed label expansion and an FDA committee sided against an AstraZeneca breast c…
biopharma_dive · 3mo ago
FDA approval for Alzheimer's agitation drug; Esperion goes private in $1.1B deal
🟢 FDA approves Axsome Therapeutics' Auvelity for Alzheimer’s agitation: Axsome said up to 76% of patients with Alzheimer’s disease have agitation, which is characterized by pacing, restlessness an…
endpoints · 3mo ago

brand

Auvelity

generic

(bupropion hydrochloride + dextromethorphan [INN])

MOA

12.1 Mechanism of Action Dextromethorphan is an uncompetitive antagonist of the NMDA receptor (an ionotropic glutamate receptor) and a sigma-1 receptor agonist. The mechanism of dextromethorphan in the treatment of MDD is unclear. The mechanism of action of bupropion in the treatment of MDD is unclear; however, it may be related to noradrenergic and/or dopaminergic mechanisms. Bupropion increases plasma levels of dextromethorphan by competitively inhibiting cytochrome P450 2D6, which catalyzes a major biotransformation pathway for dextromethorphan. Bupropion is a relatively weak inhibitor of the neuronal reuptake of norepinephrine and dopamine and does not inhibit monoamine oxidase or the reuptake of serotonin.

indication

Dementia Associated With Alzheimer's Disease

phase

marketed

Data sources

openFDA · ClinicalTrials.gov

last refreshed 28m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

News(3)

The FDA’s 505(b)(2) pathway is an underestimated engine of value creation

The biopharma industry would do well to re-embrace the 505(b)(2) path, which allows sponsors to draw on previous findings around an existing drug even as they propose modifications to it.

biospace · 25d ago

Summit’s ‘self-inflicted’ stumble; Esperion’s take-private deal

Summit’s decision to conduct an interim analysis of a closely watched trial backfired. Elsewhere, Axsome got a much-needed label expansion and an FDA committee sided against an AstraZeneca breast c…

biopharma_dive · 3mo ago

FDA approval for Alzheimer's agitation drug; Esperion goes private in $1.1B deal

🟢 FDA approves Axsome Therapeutics' Auvelity for Alzheimer’s agitation: Axsome said up to 76% of patients with Alzheimer’s disease have agitation, which is characterized by pacing, restlessness an…

endpoints · 3mo ago

(bupropion hydrochloride + dextromethorphan) ER

🐶 often sniffed alongside

indications

all catalysts(4)

Patent cliff

patents (130)

News(3)

Report a data issue

comments(0)

(bupropion hydrochloride + dextromethorphan) ER

🐶 often sniffed alongside

indications

all catalysts(4)

Patent cliff

patents (130)

News(3)

Report a data issue

comments(0)